Debt-to-equity in % of NEXIEN BIOPHARMA, INC. from Q3 2015 to Q1 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
NEXIEN BIOPHARMA, INC. quarterly Debt-to-equity history and change rate from Q3 2015 to Q1 2025.
  • NEXIEN BIOPHARMA, INC. Debt-to-equity for the quarter ending 31 Mar 2025 was -101%, a 5.41% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

NEXIEN BIOPHARMA, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 -101% +6% +5.4% 31 Mar 2025
Q4 2024 -102% +10% +8.9% 31 Dec 2024
Q3 2024 -102% +19% +15% 30 Sep 2024
Q2 2024 -103% +30% +23% 30 Jun 2024
Q1 2024 -107% +44% +29% 31 Mar 2024
Q4 2023 -112% 31 Dec 2023
Q3 2023 -121% 30 Sep 2023
Q2 2023 -134% 30 Jun 2023
Q1 2023 -151% 31 Mar 2023
Q2 2017 106% +206% 30 Jun 2017
Q1 2017 -100% 0% 0% 31 Mar 2017
Q4 2016 -100% -2% -1.9% 31 Dec 2016
Q3 2016 -100% -2% -2.1% 30 Sep 2016
Q2 2016 -100% 30 Jun 2016
Q1 2016 -100% 31 Mar 2016
Q4 2015 -98% 31 Dec 2015
Q3 2015 -98% 30 Sep 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.